touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors.
Topics covered
- Improving early detection of prostate cancer, postate specific antigen and new imaging techniques (00:20)
- Developments in systemic therapy of early, hormone sensitive metastatic prostate cancer, including the ARCHES trial data (3:30)
- New therapies for castration-resistant prostate cancer (5:45)
- Latest advances and knowledge of PARP inhibitors (6:45)
Disclosures: Arnulf Stenzl has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of EAU23
Access more content on genitourinary cancers here
